Health Advance Inc. has reached an important milestone to supply new treatment options for the growing number of people who have lingering weakness and lack of well-being following COVID and similar infections. Health Advance has now selected its contract manufacturer for its new treatment initiative and has settled on the final version of its proprietary formulation to be used for the launch of its new product in the USA. Health Advance joins respected government, pharma and business organizations that are recognizing the large scale of this problem in society and in the economy.

There are two phases to Health Advance's product launch. The first is manufacturing its now market ready formulation in trial quantities for clinical and patient evaluation. The second phase is subsequent manufacturing of larger quantities to suit the identified demand.

Because contract manufacturing has now been organized, these phases can begin. Public progress reports will be provided henceforth. The project joint venture, provisionally called Health Advance CV, will operate as a division of Health Advance Inc. to provide affected consumers with a curated nutraceutical regime for this condition through pre-packaged proprietary supplement pouches where regulations permit, utilizing advanced infusion techniques and novel combinations to deliver superior results over conventional supplement methods.

The consumer product name for the launch will be announced separately. Leader of the Health Advance Science Team for the new venture is Dr. Alvin Pettle, a practicing anti-aging and bio-identical hormone specialist. Dr. Pettle has decades of clinical experience, with a special interest in bio-identical hormone treatments.

The program being devised under Dr. Pettle's leadership creates pre-packaged supplement combinations that consumers do not otherwise have the knowledge or patience to manage without guidance.